Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More Than Y100bn Needed To Curb Medical Costs: Health Ministry (Japan)

This article was originally published in PharmAsia News

Executive Summary

Japan's ruling coalition is considering such proposals to curb medical costs as freezing a proposed increase in medical costs for the elderly and canceling new expenses to be borne by the disabled. The Health Ministry estimates that such measures would require more than 100 billion yen per year. The coalition may cancel a plan to increase out-of-pocket medical expenses for those aged 70-74 to 20% in April 2008 from the 10% currently required. The ministry estimates that 50 billion yen in new revenue sources would be needed to table the plan and keep the payment requirement at 10%. The legislation would need to be revised during the current extraordinary Diet session in order to freeze payments. Another 40 billion yen could be necessary to put on hold a plan that would require some aged 75 and older to pay medical insurance premiums under a new medical insurance scheme to launch in April. The step would not require a bill to be passed but new ordinances would have to be created. (Click here for more - May Require Paid Subscription

You may also be interested in...

Finance Watch: Have Investors Reached IPO Fatigue?

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Expediting The Expedited: How Rolling CMC Review Process Is Working For COVID-19 Vaccines

US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.

Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts